Calithera Biosciences Obtains $4,000,000 Series B Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=1f8cf748-0395-4329-95ed-8b321a79c329&Preview=1 - Date
6/1/2012 - Company Name
Calithera Biosciences - Mailing Address
341 Oyster Point Blvd. South San Francisco, CA 94080 - Company Description
The primary mission of Calithera Biosciences is to develop novel therapeutic approaches to the treatment of cancer by using small molecules to activate, rather than inhibit, enzymes. Our first program is focused on developing activators of caspases, the proteases that induce apoptosis, for the treatment of cancer. The approach of discovering activators of enzymes has the potential to be a unique and broadly applicable technology platform for developing therapies to multiple oncology indications. - Website
http://www.calithera.com - Transaction Type
Venture Equity - Transaction Amount
$4,000,000 - Transaction Round
Series B - Proceeds Purposes
Proceeds purposes were not disclosed. SEC regulatory filing. - M&A Terms
- Venture Investor
Undisclosed
